The New England journal of medicine, 2019-07, Vol.381 (4), p.317-327
2019
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- Titel
- Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer
- Ist Teil von
- The New England journal of medicine, 2019-07, Vol.381 (4), p.317-327
- Ort / Verlag
- United States: Massachusetts Medical Society
- Erscheinungsjahr
- 2019
- Quelle
- Elektronische Zeitschriftenbibliothek (Open access)
- Beschreibungen/Notizen
- Approximately 7% of pancreatic cancers occur in patients with a germline mutation in BRCA1 or BRCA2 , an alteration that compromises DNA repair. In a randomized trial in patients with metastatic pancreatic cancer that had responded to platinum-based chemotherapy, progression-free survival was nearly twice as long with olaparib than with placebo (7.4 months vs. 3.8 months).
- Sprache
- Englisch
- Identifikatoren
- ISSN: 0028-4793eISSN: 1533-4406DOI: 10.1056/NEJMoa1903387Titel-ID: cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6810605
- Format
- –
- Schlagworte
- Adenocarcinoma - drug therapy, Adenocarcinoma - genetics, Adenocarcinoma - mortality, Adenocarcinoma - secondary, Adenosine, Adult, Aged, Aged, 80 and over, Antineoplastic Agents - adverse effects, Antineoplastic Agents - therapeutic use, Antitumor activity, BRCA mutations, BRCA1 protein, BRCA2 protein, Breast cancer, Cancer therapies, Chemotherapy, Deoxyribonucleic acid, DNA, Double-Blind Method, Drug therapy, Female, Genes, BRCA1, Genes, BRCA2, Genetic aspects, Germ-Line Mutation, Health risk assessment, Humans, Intervention, Kaplan-Meier Estimate, Maintenance Chemotherapy - adverse effects, Male, Medical imaging, Metastases, Metastasis, Middle Aged, Mutation, Neoplasm Metastasis - drug therapy, Ovarian cancer, Pancreatic cancer, Pancreatic Neoplasms - drug therapy, Pancreatic Neoplasms - genetics, Pancreatic Neoplasms - mortality, Pancreatic Neoplasms - pathology, Phthalazines - adverse effects, Phthalazines - therapeutic use, Piperazines - adverse effects, Piperazines - therapeutic use, Platinum, Poly(ADP-ribose) polymerase, Progression-Free Survival, Quality of life, Ribose, Survival, Tablets, Tumors